Publications by authors named "S N Latif"

Background: Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial (NCT02008357), including cognitively unimpaired participants with brain amyloid pathology on florbetapir F 18, demonstrates that levels of plasma P-tau217, as detected by an electrochemiluminescence (ECL) immunoassay, is strong predictor of elevated cerebral amyloid on florbetapir PET in cognitively unimpaired individuals. Here we compare plasma P-tau217 measures over 12 weeks using a P-tau217 ECL immunoassay.

Method: A4 trial placebo-group participants who had their first baseline and first post-baseline plasma P-tau217 samples collected within 175 days of each other were included in these analyses.

View Article and Find Full Text PDF

Leukemia, a life-threatening form of cancer, poses a significant global health challenge affecting individuals of all age groups, including both children and adults. Currently, the diagnostic process relies on manual analysis of microscopic images of blood samples. In recent years, machine learning employing deep learning approaches has emerged as cutting-edge solutions for image classification problems.

View Article and Find Full Text PDF

The Internet of Things (IoT) paradigm is a foundational and integral factor for the development of smart applications in different sectors. These applications are comprised over set of interconnected modules that exchange data and realize the distributed data flow (DDF) model. The execution of these modules on distant cloud data-center is prone to quality of service (QoS) degradation.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effectiveness and safety of Semaglutide, a weight loss medication, in obese patients with and without Type II Diabetes Mellitus over a period from August 2022 to January 2023.
  • A total of 65 obese participants were monitored, starting with a low dose of Semaglutide that increased every four weeks, with most patients settling on 0.5 mg after three months, and some on higher doses after six months.
  • Results showed an average weight loss of around 5.81 kg at three months and 9.86 kg at six months, with about 55.4% of patients experiencing mild to moderate gastrointestinal side effects, which decreased over time and did not
View Article and Find Full Text PDF